Synlogic

DESIGNED FOR LIFE

SYNB1618
Phase1/2a Clinical Trial
Topline Data from PKU Patient Cohorts
July 15th, 2019



synlogic

SYNB1618 Potential to Address Unmet Need Across Patient Groups



synlogic

SYNB1618 Phase 1/2a Study Design



PKU Clinical Trial Design

- Randomized, double-blind placebo-controlled study at multiple sites in the US
- Primary outcome: establish safety/tolerability following single and multiple doses in HV and PKU patients
- Secondary outcome: SYNB1618 kinetics in feces
- Exploratory: change from baseline in plasma and urinary biomarkers of Phe metabolism

SYNB1618 Activity Biomarkers Indicate Significant Phe Consumption

Similar activity in HVs and PKU Patients



HA=hippurate, D5-HA= labeled HA,
CFB=change from baseline, CFP=change from placebo
HV=healthy volunteer
PKU=phenylketonuria patient

Modeling: Potential For Phe Reduction in PKU Patients



Ranges represent

- Low: PAL mechanism only (conservative)
- High: PAL + LAAD activity (estimates maximum with both pathways)

Upcoming Milestones and Path Forward

- Established new solid formulation and manufacturing process ✓
- Completed EPO1 interactions with FDA to align on program plans (clinical, manufacturing, toxicology) ✓
- Completed Phase 1/2a study (healthy volunteers and PKU patients) ✓
- Initiate bridging study with solid formulation in Q3 2019
- Phase 2 study in PKU patients to assess Phe lowering to start in 1H 2020

synlogic

301 BINNEY ST., #402, CAMBRIDGE, MA 02142
TEL: 617-401-9975
WEB: WWW.SYNLOGICTX.COM | EMAIL: INFO@SYNLOGICTX.COM